Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252201 | 0.90 | SKP2 (0.41) | CYP1A2CYP2A6SIGMAR1LPLLIPG | |
| SCHEMBL2252129 | 0.87 | GPR3 (0.42) | LPLLIPG | |
| SCHEMBL5746343 | 0.87 | GPR3 (0.42) | LPLLIPG | |
| SCHEMBL1972165 | 0.87 | GPR3 (0.42) | LPLLIPG | |
| SCHEMBL8625941 | 0.86 | CNR1 (0.39) | CNR1CNR2CYP1A2CYP2A6SIGMAR1 | |
| SCHEMBL4950178 | 0.85 | CYP1A2 (0.53) | CYP1A2CYP2A6SIGMAR1MEN1GAA | |
| SCHEMBL2256224 | 0.78 | SIGMAR1 (0.42) | CYP1A2CYP2A6SIGMAR1BCHE | |
| SCHEMBL2254826 | 0.78 | SIGMAR1 (0.42) | CYP1A2CYP2A6SIGMAR1BCHE | |
| SCHEMBL7519330 | 0.77 | LMNA (0.39) | CYP1A2CYP2A6PDK2 | |
| SCHEMBL1970551 | 0.76 | CYP1A2 (0.38) | CNR1CNR2CYP1A2CYP2A6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| CN-107085033-A | N phenylnaphthalenes aminated compounds as MALDI matrix application | 中国科学院化学研究所 | 2017-08-22 | — | — | CN | disclosed |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2016-11-24 | — | — | US | disclosed |
| EP-1411912-A1 | TREATMENT OF CHRONIC PAIN WITH 3-ARYLOXY-3-PHENYLPROPANAMINES | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1411934-A1 | TREATMENT OF CHRONIC PAIN WITH 3-HETEROCYCLYL- AND 3-CYCLOALKYL-3-ARYLOXYPROPANAMINES | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030087965-A1 | Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines | PHARMACIA & UPJOHN COMPANY | 2003-05-08 | — | — | US | disclosed |
| US-20030087938-A1 | Treatment of chronic pain with 3-heterocycloxy-and 3-cycloalkyloxy-3-phenylpropanamines | PHARMACIA & UPJOHN COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2003011289-A1 | TREATMENT OF CHRONIC PAIN WITH 3-HETEROCYCLYL- AND 3-CYCLOALKYL-3-ARYLOXYPROPANAMINES | PHARMACIA + UPJOHN COMPANY (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011272-A1 | TREATMENT OF CHRONIC PAIN WITH 3-ARYLOXY-3-PHENYLPROPANAMINES | PHARMACIA & UPJOHN COMPANY (US) | 2003-02-13 | — | — | WO | disclosed |
| US-6410777-B1 | HALOGEN-FREE | TEIJIN LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-0980861-A1 | SALICYLIC ESTER DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | TEIJIN LIMITED (JP) | 2000-02-23 | — | — | EP | disclosed |
| US-5852221-A | Optically active β-aminoalkoxyborane complex | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-12-22 | — | — | US | disclosed |
| US-5808098-A | REDUCING AGENT FROM AMINOALCOHOL | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0680484-B1 | OPTICALLY ACTIVE BETA-AMINOALKOXYBORANE COMPLEXES | NISSAN CHEMICAL IND LTD (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5786485-A | REACTING OPTICALLY ACTIVE BETA-AMINOALCOHOL WITH BORANE REAGENT TO PRODUCE OPTICALLY ACTIVE BETA-AMINOALKOXYBORANE COMPLEX | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-07-28 | — | — | US | disclosed |
| US-5767277-A | REDUCING AGENT FOR A CARBONYL COMPOUND TO PRODUCE A 1,3-SYN-DIOL COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| US-5739347-A | REDUCING AGENTS FOR DECARBONYLATION | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5663348-A | REDUCTION OF DIKETONE WITH AMINOALKOXYBORANE COMPLEX TO FORM DIALCOHOL ESTER COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1997-09-02 | — | — | US | disclosed |
| EP-0680484-A1 | OPTICALLY ACTIVE $g(b)-AMINOALKOXYBORANE COMPLEX | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017079-A1 | OPTICALLY ACTIVE β-AMINOALKOXYBORANE COMPLEX | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | CNR1 1008/4885CNR2 915/4885CYP1A2 360/4885 |
| US-20160342084-A1 | ACID- AND RADICAL-GENERATING AGENT AND METHOD FOR GENERATING ACID AND RADICAL | CBR1, HAO2, CBR3 | CNR1 1008/4885CNR2 915/4885CYP1A2 360/4885 |
| US-20030087965-A1 | Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines | PNMT, OPRL1, OPRK1 | CNR1 17/4885CNR2 7/4885CYP1A2 806/4885 |
| US-20030087938-A1 | Treatment of chronic pain with 3-heterocycloxy-and 3-cycloalkyloxy-3-phenylpropanamines | OPRK1, CNR2, OPRL1 | CNR1 4/4885CNR2 2/4885CYP1A2 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.